Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 4/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608469 | 0.94 | MAPT (0.52) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL7606764 | 0.92 | MAPT (0.55) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL7603258 | 0.92 | MAPT (0.55) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL42941 | 0.89 | MAPT (0.59) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL356035 | 0.89 | MAPT (0.53) | MAPTLMNAKDM4EDUSP3MEN1 | |
| Alcohol SCHEMBL28251605 | 0.87 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL496450 | 0.86 | MAPT (0.62) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL495250 | 0.86 | MAPT (0.62) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL495197 | 0.86 | MAPT (0.62) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL495181 | 0.86 | MAPT (0.62) | MAPTLMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| EP-1874767-A2 | PRODUCTION OF DOLASETRON | Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság (HU) | 2008-01-09 | — | — | EP | disclosed |
| EP-1861397-A2 | PRODUCTION OF DOLASETRON | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság (HU) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007081889-A9 | PRODUCTION OF DOLASETRON | TEVA GYOGYSZERGYAR ZARTKORUEN (HU) | 2007-09-20 | — | — | WO | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007081889-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081890-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | disclosed |
| US-6521762-B2 | Using a base in solvent | BIOGAL Gyógyszergyar RT. (HU) | 2003-02-18 | — | — | US | disclosed |
| EP-1140847-B1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AG (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-6448205-B1 | FOR THE DESICCATION AND/OR DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-10 | — | — | US | disclosed |
| US-6432880-B1 | APPLYING TO PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| WO-2002042275-A1 | 2-ARYL-5-TRIFLUOROMETHYLPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| US-6383986-B1 | USE AS HERBICIDES, DESICCANTS OR DEFOLIANTS AND PLANT SAFENING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-07 | — | — | US | disclosed |
| WO-2001087863-A1 | 3-ARYLISOTHIAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-22 | — | — | WO | disclosed |
| US-5270322-A | Imidazo[1,2-a]pyridines, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1993-12-14 | — | — | US | disclosed |
| CN-1036204-A | some compounds | ISF SPA (IT) | 1989-10-11 | — | — | CN | disclosed |
| EP-0208272-A2 | Method for the preparation of alkyl esters of 3,4-epoxybutyric acid | TECNOPART S.r.l. (IT) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | MAPT 4280/4885LMNA 3913/4885KDM4E 1384/4885 |
| US-20070203219-A1 | Production of dolasetron | DDOST, DAD1, DHPS | MAPT 3789/4885LMNA 1206/4885KDM4E 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.